SCHEMBL1667296

SCHEMBL1667296

COc1ccc(Nc2nc(-c3cccc(C#N)c3)c3ccccc3n2)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 10/20 0.60
LMNA P02545 3/20 0.55
MAPT P10636 3/20 0.55
MAPK1 P28482 2/20 0.55
ADORA1 P30542 2/20 0.54
ADORA2B P29275 1/20 0.54
ADORA2A P29274 2/20 0.53
ABCB1 P08183 4/20 0.52
ABCC1 P33527 2/20 0.52
FLT3 P36888 1/20 0.52
MEN1 O00255 4/20 0.50
CYP1A2 P05177 4/20 0.50
KMT2A Q03164 4/20 0.50
CYP2C19 P33261 3/20 0.50
TSHR P16473 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP3A4 P08684 2/20 0.50
CLK4 Q9HAZ1 2/20 0.50
USP2 O75604 1/20 0.50
CYP2D6 P10635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12275273 0.87 MAPT (0.53) ABCG2LMNAMAPTMAPK1ADORA1
SCHEMBL12801596 0.84 MAPT (0.58) ABCG2LMNAMAPTMAPK1ABCB1
SCHEMBL12801627 0.81 MAPT (0.56) ABCG2LMNAMAPTMAPK1ABCB1
SCHEMBL12274826 0.80 FLT3 (0.52) ABCG2ADORA1ADORA2BFLT3TSHR
SCHEMBL12275237 0.80 PAK1 (0.58) FLT3
SCHEMBL12522240 0.79 FLT3 (0.49) ABCG2MAPTADORA1ADORA2BADORA2A
SCHEMBL12275178 0.78 FLT3 (0.54) ABCG2ADORA1ADORA2BFLT3CYP1A2
SCHEMBL12274361 0.76 MEN1 (0.56) ABCG2FLT3MEN1KMT2A
SCHEMBL12274278 0.75 MAPT (0.60) ABCG2LMNAMAPTMAPK1ABCB1
SCHEMBL6034261 0.73 KDR (0.73) ADORA1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150352108-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON ALZHEIMER'S INSTITUTE OF AMERICA (US) 2015-12-10 US disclosed
US-20150352108-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON ALZHEIMER'S INSTITUTE OF AMERICA (US) 2015-12-10 US disclosed
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 MYREXIS, INC. (US) 2012-09-20 US disclosed
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 MYREXIS, INC. (US) 2012-09-20 US disclosed
EP-2488503-A1 AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON Myrexis, Inc. (US) 2012-08-22 EP disclosed
WO-2011046970-A1 AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON MYREXIS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352108-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON TBK1, NFKBIA, CHUK ABCG2 1352/4885LMNA 2945/4885MAPT 1262/4885
US-20120238540-A1 AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 TBK1, NFKBIA, IKBKB ABCG2 1277/4885LMNA 2335/4885MAPT 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.